ICD-10 Logo
ICDxICD-10 Medical Coding
ICD-10 Logo
ICDxICD-10 Medical Coding
ICD 10 CodesDiagnoses
ICD 10 CodesDiagnoses
ICD-10 Logo
ICDxICD-10 Medical Coding

Comprehensive ICD-10-CM code reference with AI-powered search capabilities.

© 2025 ICD Code Compass. All rights reserved.

Browse

  • All Chapters
  • All Categories
  • Diagnoses

Tools

  • AI Code Search
ICD-10-CM codes are maintained by the CDC and CMS. This tool is for reference purposes only.
v1.0.0
ICD-10 Guide
ICD-10 CodesJ66.2

J66.2

Cannabinosis

BILLABLE STATUSYes
IMPLEMENTATION DATEOctober 1, 2015
LAST UPDATED09/06/2025

Code Description

ICD-10 J66.2 is a billable code used to indicate a diagnosis of cannabinosis.

Key Diagnostic Point:

Cannabinosis refers to a respiratory condition resulting from the inhalation of cannabis smoke, which can lead to various lung-related issues. Clinically, patients may present with symptoms such as chronic cough, wheezing, and dyspnea. The anatomy involved primarily includes the bronchial passages and lung parenchyma, where inflammation and irritation can occur due to the inhalation of particulate matter and other harmful substances found in cannabis smoke. Disease progression may vary, with some individuals experiencing acute symptoms that resolve upon cessation of use, while others may develop chronic bronchitis-like symptoms or exacerbate pre-existing respiratory conditions. Diagnostic considerations include a thorough patient history, physical examination, and possibly imaging studies or pulmonary function tests to assess lung function and rule out other conditions. It is crucial to differentiate cannabinosis from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD) or asthma, to ensure appropriate management and treatment.

Code Complexity Analysis

Complexity Rating: Medium

Medium Complexity

Complexity Factors

  • Diagnostic complexity: Requires a detailed patient history and exclusion of other respiratory conditions.
  • Treatment complexity: Management may involve cessation of cannabis use and symptomatic treatment.
  • Documentation requirements: Comprehensive documentation of symptoms, history, and diagnostic tests is essential.
  • Coding specificity: Specific to cannabis-related respiratory issues, but may overlap with other respiratory codes.

Audit Risk Factors

  • Common coding errors: Misclassification with other respiratory conditions.
  • Documentation gaps: Incomplete patient history or lack of symptom documentation.
  • Billing challenges: Potential denials if documentation does not clearly support the diagnosis.

Specialty Focus

Medical Specialties

Pulmonology

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Primary Care

Documentation Requirements

Standard ICD-10-CM documentation requirements apply

Common Clinical Scenarios

Various clinical presentations within this specialty area

Billing Considerations

Follow specialty-specific billing guidelines

Related CPT Codes

CPT Code

Clinical Scenario

Documentation Requirements

CPT Code

Clinical Scenario

Documentation Requirements

ICD-10 Impact

Diagnostic & Documentation Impact

Enhanced Specificity

ICD-10 Improvements

Cannabinosis has clinical significance as it highlights the respiratory risks associated with cannabis use, particularly as legalization increases its prevalence. Understanding this condition can inform public health initiatives aimed at educating users about potential lung health impacts. Additionally, it may influence healthcare utilization patterns, as patients may seek care for respiratory symptoms related to cannabis use. Epidemiologically, as cannabis becomes more widely used, monitoring the incidence of cannabinosis will be crucial for assessing its impact on population health.

ICD-9 vs ICD-10

Cannabinosis has clinical significance as it highlights the respiratory risks associated with cannabis use, particularly as legalization increases its prevalence. Understanding this condition can inform public health initiatives aimed at educating users about potential lung health impacts. Additionally, it may influence healthcare utilization patterns, as patients may seek care for respiratory symptoms related to cannabis use. Epidemiologically, as cannabis becomes more widely used, monitoring the incidence of cannabinosis will be crucial for assessing its impact on population health.

Reimbursement & Billing Impact

Reimbursement considerations may vary by payer, so it is important to verify coverage policies. Common denials may arise from insufficient documentation or failure to establish a clear link between cannabis use and respiratory symptoms. Best practices include thorough documentation of all relevant clinical findings and ensuring that the coding accurately reflects the patient's condition.

Resources

Clinical References

  • •
    ICD-10 Official Guidelines for J00-J99
  • •
    Clinical Documentation Requirements

Coding & Billing References

  • •
    ICD-10 Official Guidelines for J00-J99
  • •
    Clinical Documentation Requirements

Frequently Asked Questions

What specific conditions are covered by J66.2?

J66.2 specifically covers respiratory conditions related to cannabis smoke exposure, including chronic bronchitis-like symptoms and other lung irritations caused by inhalation of cannabis.

When should J66.2 be used instead of related codes?

J66.2 should be used when the respiratory symptoms are directly attributable to cannabis use, distinguishing it from other respiratory conditions that may not involve cannabis exposure.

What documentation supports J66.2?

Documentation should include a detailed patient history of cannabis use, symptom descriptions, physical examination findings, and any diagnostic tests performed to evaluate lung function.